Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)

被引：0
|
作者：
Wang, J. [1 ]
Cheng, Y. [2 ]
Wu, Y-L. [3 ]
An, T. [4 ]
Gao, H. [5 ]
Wang, K. [6 ]
Zhou, Q. [3 ]
Hu, Y. [7 ,13 ]
Song, Y. [8 ]
Ding, C. [9 ]
Ye, X. [10 ]
Peng, F. [11 ]
Liang, L. [12 ]
Hu, Y. [7 ,13 ]
Huang, C. [14 ]
Zhou, C. [15 ]
Shi, Y-K. [16 ]
Zhang, L. [17 ]
Gu, Y. [10 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Internal Med, Beijing, Peoples R China
[2] Jilin Prov Canc Hosp, Med Oncol, Changchun, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[4] Peking Univ, Canc Hosp, Beijing Canc Hosp, Thorac Med Oncol, Beijing, Peoples R China
[5] PLA AMMS China, Hosp 307, Med Oncol, Beijing, Peoples R China
[6] Zhejiang Canc Hosp, Genet, Hangzhou, Zhejiang, Peoples R China
[7] Hubei Prov Tumor Hosp, Med Oncol, Wuhan, Peoples R China
[8] Nanjing Mil Gen Hosp, Oncol, Nanjing, Jiangsu, Peoples R China
[9] Hebei Prov Tumor Hosp, Oncol, Shijiazhuang, Peoples R China
[10] AstraZeneca, Asia & Emerging Markets iMed, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[12] Beijing Univ, Hosp 3, Med Oncol, Beijing, Peoples R China
[13] Chinese Peoples Liberat Army Gen Hosp, Med Oncol, Beijing, Peoples R China
[14] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Peoples R China
[15] Tongji Univ, Tongji Hosp, Lung Canc Oncol & Immunol, Shanghai, Peoples R China
[16] Chinese Acad Med Sci, Canc Inst & Hosp, Med Oncol, Beijing, Peoples R China
[17] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.88
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1288TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW
    Huerfano, C.
    NinoNino, C. P.
    Davila, F.
    Reyes, J. M.
    Diaz, J. A.
    VALUE IN HEALTH, 2016, 19 (03) : A169 - A169
  • [32] Circulating tumor cells and detection of EGFR mutation in cell-free tumor DNA in blood plasma in metastatic non-small cell lung cancer with EGFR mutation.
    Isobe, K.
    Hata, Y.
    Sakaguchi, S.
    Sato, K.
    Sugino, K.
    Sano, G.
    Sakamoto, S.
    Takai, Y.
    Shibuya, K.
    Takagi, K.
    Homma, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
    Lopes, Gilberto de Lima, Jr.
    Segel, Joel E.
    Tan, Daniel S. W.
    Do, Young K.
    Mok, Tony
    Finkelstein, Eric A.
    CANCER, 2012, 118 (04) : 1032 - 1039
  • [34] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian Shu Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing China
    Journal of Nanjing Medical University, 2009, 23 (06) : 392 - 397
  • [35] Comparison of the efficacy and safety of icotinib with vinorelbine or without vinorelbine as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A retrospective study
    Xu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1586
  • [36] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [37] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin1
    The Journal of Biomedical Research, 2009, (06) : 392 - 397
  • [38] COST-UTILITY ANALYSIS OF GEFITINIB AND EGFR MUTATION TESTING AS THE FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    VALUE IN HEALTH, 2017, 20 (05) : A112 - A112
  • [39] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    T. Masuda
    H. Imai
    T. Kuwako
    Y. Miura
    R. Yoshino
    K. Kaira
    K. Shimizu
    N. Sunaga
    Y. Tomizawa
    S. Ishihara
    A. Mogi
    T. Hisada
    K. Minato
    A. Takise
    R. Saito
    M. Yamada
    Clinical and Translational Oncology, 2015, 17 : 702 - 709
  • [40] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    Masuda, T.
    Imai, H.
    Kuwako, T.
    Miura, Y.
    Yoshino, R.
    Kaira, K.
    Shimizu, K.
    Sunaga, N.
    Tomizawa, Y.
    Ishihara, S.
    Mogi, A.
    Hisada, T.
    Minato, K.
    Takise, A.
    Saito, R.
    Yamada, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 702 - 709
12345